Boswellia (Indian Frankincense): A Plant for Joints and Inflammation, What the Research Says

Frankincense is one of the oldest substances known to humanity. Thousands of years ago, this fragrant resin was burned in temples, used in high-value trade along the Incense Route, and considered as precious as gold. What is less known is that the same resin, extracted from trees of the genus Boswellia, was also used in traditional Indian medicine, Ayurveda, to treat inflammation, joint pain, and a variety of diseases. The Indian variety, Boswellia serrata, is the one that has received the most scientific attention.

In recent decades, Boswellia has returned to the forefront, this time as a popular dietary supplement for joints and inflammation. The active components in the resin, a group of substances called boswellic acids, primarily a molecule named AKBA, show a clear and interesting anti-inflammatory mechanism in laboratory studies. But what sets Boswellia apart from many other joint herbs is that behind the mechanism, there is also a relatively decent body of human evidence, including a meta-analysis and several controlled clinical trials. In this article, we will separate facts from hype, review the evidence, and explain why we rated Boswellia yellow, as one of the more promising options in the joint category, but with reservations that are important to know.

What is Boswellia?

Boswellia is the name of a genus of trees from which a fragrant resin, known as frankincense and Indian frankincense, is extracted. The most medically researched variety is Boswellia serrata, which grows mainly in India. Here is what is important to understand:

• The active substance is the resin, not the leaves. When the tree trunk is cut, a resin is secreted that hardens into lumps. This dried resin, and its concentrated extracts, are the basis for supplements.
• The active components are boswellic acids. These are a group of substances of the triterpene type. The most important of these is considered to be AKBA, an acronym for acetyl-11-keto-beta-boswellic acid, which is the most potent inhibitor of a central inflammatory pathway.
• Concentration matters. Standardized supplements indicate the percentage of total boswellic acids, and sometimes also the percentage of AKBA. Patented preparations like Aflapin or 5-Loxin are enriched with AKBA to enhance the effect.
• The primary use is for joints. Boswellia is mainly marketed for relieving joint pain and inflammation, primarily in knee osteoarthritis (osteoarthritis), but has also been examined in other inflammatory conditions.

An important point for the consumer: the quality of the supplement varies greatly between brands. A product containing a high percentage of boswellic acids and explicitly stating the AKBA content will be closer to the preparations tested in studies than raw resin powder of unknown concentration. This is one of the reasons for the importance of informed choice.

The Connection to Inflammation and Joints: An Interesting Mechanism

The mechanism of Boswellia is one of the things that makes it particularly interesting, because it differs from that of common pain relievers. While non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen act on the COX enzyme, Boswellia acts on a completely different inflammatory pathway.

First mechanism, inhibition of the enzyme 5-lipoxygenase. This is the central mechanism. The AKBA molecule inhibits the enzyme 5-lipoxygenase (5-LOX), which is responsible for producing leukotrienes, primarily leukotriene B4. These leukotrienes are potent inflammatory mediators that activate white blood cells and increase the inflammatory process. Blocking their production reduces the inflammatory load in the joint. This is a pathway that NSAIDs hardly touch, and therefore Boswellia is considered complementary, not overlapping, to them.

Second mechanism, effect on NF-kappaB. Boswellic acids suppress the activation of the transcription factor NF-kappaB, which is a kind of "master switch" of inflammation in the cell. Suppressing it reduces the expression of many inflammatory cytokines, thereby broadening the anti-inflammatory effect beyond the leukotriene pathway alone.

Third mechanism, protection of cartilage. Laboratory studies have shown that Boswellia reduces the activity of the enzyme MMP-3, which breaks down the cartilage matrix in the joint. If this finding is confirmed in humans, it would mean that Boswellia not only relieves pain but may also slow the degenerative process itself, although this is currently a hypothesis based mainly on animal models. It is important to emphasize that the second and third mechanisms are based primarily on laboratory work, and the most solid clinical proof is for pain relief and functional improvement.

Current Evidence

Study 1: Comprehensive Meta-Analysis, Yu et al. 2020

This is the cornerstone of the evidence in the field. In 2020, Yu and colleagues published a systematic review and meta-analysis in the journal BMC Complementary Medicine and Therapies that collected seven controlled clinical trials, with a total of 545 patients with osteoarthritis. This is precisely the level of evidence that is lacking for most joint herbs, and here it exists.

The analysis examined accepted and validated measures: the Visual Analog Scale (VAS) for pain and the WOMAC index with its subscales for pain, stiffness, and function, as well as the Lequesne index. The researchers found that Boswellia and its extracts led to significant relief in pain and stiffness compared to the control group, and to an improvement in function. Their conclusion was that Boswellia may be an effective and relatively safe treatment option for osteoarthritis patients, and that the recommended minimum treatment duration for effect is at least 4 weeks. However, the researchers also noted limitations: variability between preparations and dosages, and variable methodological quality of some trials.

Study 2: AKBA-Enriched Preparation, Sengupta et al. 2010

One of the most notable findings regarding Boswellia is the speed of its effect. In 2010, Sengupta and colleagues published a double-blind, placebo-controlled trial involving 60 patients with knee osteoarthritis, who received an AKBA-enriched preparation (Aflapin) or a placebo.

The results showed significant improvement in pain scores (VAS) and the WOMAC index after only 5 to 7 days, not just after weeks. The improvement continued and strengthened until the end of the trial at days 30 and 90. This speed of effect, which is not typical of slow-acting cartilage supplements like glucosamine, is one of the practical advantages of Boswellia. It is important to qualify: this was a small sample and a specific patented preparation, so it should not be assumed that every Boswellia product will work with the same speed or at all.

Study 3: Recent Multi-Center Trial, 2024

The evidence continues to accumulate in recent years as well. A double-blind, randomized, multi-center, placebo-controlled trial published in 2024 in the journal Frontiers in Pharmacology examined a standardized Boswellia extract in patients with knee osteoarthritis, in a three-arm design.

The trial reported improvement in knee osteoarthritis symptoms within 5 days, consistent with the speed findings from previous studies. Such a large, well-controlled trial strengthens the overall picture that Boswellia is not only active in the lab but provides measurable relief in humans. However, as always, it is important to remember that standardized preparations in trials are not necessarily identical to the product on the shelf, and that herbal treatment is not a substitute for a medical evaluation of the source of pain.

What About Other Inflammations and Bowel Diseases?

Beyond osteoarthritis, Boswellia has also been examined in other inflammatory conditions, although the evidence there is weaker. Due to its inhibition of the leukotriene pathway, it has been studied in inflammatory bowel diseases like ulcerative colitis and Crohn's disease, in asthma, and in other inflammatory conditions. Some early trials in these areas were small and encouraging, but they are far from conclusive, and Boswellia is not a substitute for standard medical treatment for these diseases.

It is important to clarify the limits: Boswellia is not a cure for autoimmune diseases, does not heal bowel diseases, and is not a substitute for prescription anti-inflammatory drugs. Its strongest evidence is concentrated in joints, particularly knee osteoarthritis. For other indications, it is currently an interesting research direction, not a established recommendation. The bottom line is the same for any supplement: even when the mechanism is promising, one must rely on what has been proven, and in the case of Boswellia, that is pain and function in the joint, not much beyond that.

Should You Start Taking Boswellia?

This is the reason we rated Boswellia yellow, but yellow on the strong side of the scale. There is a clear mechanism, there is a human meta-analysis, and there are several controlled trials pointing to real relief. But caution and judgment are still needed. Here is what is important to know:

• Generally well-tolerated. In trials, the safety profile of Boswellia was good, and side effects were usually mild. The most common are gastrointestinal discomfort, such as nausea, heartburn, or diarrhea, and occasionally a rash. This is a significant advantage over chronic use of NSAIDs, which can damage the stomach.
• Caution in pregnancy and breastfeeding. There are not enough safety data, and traditionally the plant has even been linked to effects on the uterus. Pregnant or breastfeeding women should avoid it.
• Possible interactions with medications. Due to its anti-inflammatory activity, Boswellia may enhance the effect or risk of other anti-inflammatory drugs. There may also be interactions with immunosuppressant drugs and with drugs metabolized by the same liver enzymes. Anyone taking regular medications, especially blood thinners or immunosuppressants, should consult a doctor or pharmacist.
• Cost and dosage. A high-quality, standardized Boswellia supplement, especially an AKBA-enriched preparation, costs more than raw resin powder. Dosages tested in studies typically ranged around several hundred milligrams of standardized extract per day, sometimes divided. It is advisable to choose a product that states the concentration and AKBA content.
• It does not diagnose the source of pain. Joint pain can stem from many causes. Boswellia may relieve symptoms of osteoarthritis, but it is not a substitute for a medical diagnosis of the problem, especially if the pain is new, severe, or accompanied by swelling, fever, or significant limitation of movement.

Beyond all this, one must also remember the quality issue. Since the concentration of boswellic acids and AKBA varies greatly between products, it is difficult to know in advance whether the product you choose is similar to the preparations tested in studies. As always: the absence of a dramatic warning on the label is not a guarantee that the supplement is safe or effective for everyone.

What to Take Away from the Research?

1. If you have knee osteoarthritis, this is one of the more supported herbal options. Among joint herbs, Boswellia has a human meta-analysis and a clear mechanism. It can be considered as an addition to treatment, but it is advisable to do so in consultation, and not to replace established treatment with it.
2. Look for a standardized preparation. Choose a product that specifies the percentage of boswellic acids, and preferably also the AKBA content. An AKBA-enriched preparation is closer to what was tested in studies that showed a rapid effect.
3. Give it time, but not too much. Some users feel relief within days to a week, but to judge the effect, it is advisable to try for at least 4 weeks, according to the meta-analysis recommendation.
4. If you take regular medications, consult first. Especially with blood thinners, immunosuppressants, or other anti-inflammatory drugs, check for interactions with a doctor or pharmacist.
5. Don't neglect the basics. Joint health is built primarily from maintaining a healthy weight, strengthening muscles, regular movement, and sleep. Boswellia can be a beneficial addition, not a substitute.

For those interested in examining the plant from a reliable source, you can purchase Boswellia on iHerb and choose brands that specify the concentration of boswellic acids and the AKBA content. But remember: with a joint supplement, personal suitability and informed choice are no less important than the dosage. To check which supplements are truly suitable for your health goals, including joint health, according to your age and condition, you can use our personal supplement checker that rates each supplement according to the quality of evidence.

The Broader Perspective

Boswellia is an interesting example of a plant that manages to pass the most difficult test: not only being active in vitro, but showing measurable results in humans in controlled trials. On one hand, it is one of the most evidence-supported joint herbs, with a unique anti-inflammatory mechanism through inhibition of 5-lipoxygenase, with a meta-analysis finding relief in pain and stiffness, and with a relatively favorable safety profile. On the other hand, the effect size is moderate, the quality of preparations is not uniform, and caution is needed in certain populations. This is precisely the profile of a strong yellow supplement: not a miracle, but also not an empty promise.

The practical lesson is twofold. First, there is a real difference between a plant marketed with a nice story and a plant backed by human evidence. Boswellia belongs to the second group, and that is what distinguishes it from many "miracle herbs" for joints. Second, even a supported supplement is part of a larger picture. The most effective treatment for osteoarthritis is built from a combination of movement, strengthening the muscles around the joint, maintaining weight, and sometimes physical therapy, and Boswellia can be a supporting component in it, not the main star. And that is precisely the perspective we hold here: to rate each supplement according to what the science truly shows, to point out what is promising, and to always remember that even the best supplement works best when it sits on a foundation of healthy habits.

References:
Yu G. et al., Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis, BMC Complementary Medicine and Therapies, 2020;20(1):225
Sengupta K. et al., Comparative efficacy and tolerability of 5-Loxin and Aflapin against osteoarthritis of the knee: a double blind, randomized, placebo controlled clinical study, International Journal of Medical Sciences, 2010;7(6):366-377
A standardized Boswellia serrata extract shows improvements in knee osteoarthritis within five days: a double-blind, randomized, three-arm, parallel-group, multi-center, placebo-controlled trial, Frontiers in Pharmacology, 2024